Clinical Trial

Study of ZGGS34 in Participants With Advanced Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a multicenter, open-label Phase 1/2 study in participants with advanced solid tumors. The study consists of two parts: Part 1 is a dose-escalation phase to evaluate the safety and tolerability of ZGGS34 in advanced solid tumor participants; Part 2 is a cohort-expansion phase to assess the efficacy and safety of ZGGS34 (± chemotherapy) in selected MUC17-positive advanced solid tumor participants.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-20.
Status change: Not Yet Recruiting → Recruiting 2026-04-27
Trial Details
NCT Number NCT07258121
Lead Sponsor Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Conditions Solid Tumor
Enrollment 400 participants
Start Date 2025-12-31
Primary Completion 2028-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-28